O	0	1	[	[	(	O
O	1	4	The	The	DT	B-NP
O	5	9	erbB	erbB	NN	I-NP
O	10	14	gene	gene	NN	I-NP
O	15	21	family	family	NN	I-NP
O	21	22	:	:	:	O
O	23	35	significance	significance	NN	B-NP
O	36	39	for	for	IN	B-PP
B-Cancer	40	45	tumor	tumor	NN	B-NP
O	46	57	development	development	NN	I-NP
O	57	58	,	,	,	O
O	59	68	prognosis	prognosis	NN	B-NP
O	69	72	and	and	CC	O
O	73	76	new	new	JJ	B-NP
O	77	88	therapeutic	therapeutic	JJ	I-NP
O	89	99	modalities	modality	NNS	I-NP
O	99	100	]	]	)	O
O	100	101	.	.	.	O

O	103	106	RNA	RNA	NN	B-NP
O	107	110	and	and	CC	I-NP
O	111	114	DNA	DNA	NN	I-NP
O	115	122	viruses	virus	NNS	I-NP
O	123	126	can	can	MD	B-VP
O	127	129	be	be	VB	I-VP
O	130	142	transforming	transform	VBG	I-VP
O	143	146	and	and	CC	O
O	147	159	tumourigenic	tumourigenic	JJ	B-NP
O	160	166	agents	agent	NNS	I-NP
O	166	167	.	.	.	O

O	168	171	The	The	DT	B-NP
O	172	186	transformation	transformation	NN	I-NP
O	187	189	is	be	VBZ	B-VP
O	190	191	a	a	DT	B-NP
O	192	203	consequence	consequence	NN	I-NP
O	204	206	of	of	IN	B-PP
O	207	210	the	the	DT	B-NP
O	211	218	ability	ability	NN	I-NP
O	219	221	of	of	IN	B-PP
O	222	229	viruses	virus	NNS	B-NP
O	230	232	to	to	TO	B-VP
O	233	242	integrate	integrate	VB	I-VP
O	243	247	into	into	IN	B-PP
O	248	251	the	the	DT	B-NP
O	252	256	host	host	NN	I-NP
B-Cell	257	261	cell	cell	NN	I-NP
O	261	262	'	'	POS	B-NP
O	262	263	s	s	NN	I-NP
O	264	267	DNA	DNA	NN	I-NP
O	268	271	and	and	CC	O
O	272	274	to	to	TO	B-VP
O	275	282	produce	produce	VB	I-VP
O	283	295	transforming	transform	VBG	I-VP
O	296	304	proteins	protein	NNS	B-NP
O	304	305	.	.	.	O

O	306	311	These	These	DT	B-NP
O	312	320	proteins	protein	NNS	I-NP
O	321	324	are	be	VBP	B-VP
O	325	331	mainly	mainly	RB	I-VP
O	332	340	produced	produce	VBN	I-VP
O	341	343	by	by	IN	B-PP
O	344	352	specific	specific	JJ	B-NP
O	353	361	integral	integral	JJ	I-NP
O	362	367	parts	part	NNS	I-NP
O	368	370	of	of	IN	B-PP
O	371	374	the	the	DT	B-NP
O	375	380	viral	viral	JJ	I-NP
O	381	387	genome	genome	NN	I-NP
O	387	388	,	,	,	O
O	389	392	the	the	DT	B-NP
O	393	402	oncogenes	oncogene	NNS	I-NP
O	402	403	.	.	.	O

O	404	414	Comparison	Comparison	NN	B-NP
O	415	422	between	between	IN	B-PP
O	423	426	RNA	RNA	NN	B-NP
O	426	427	/	/	SYM	I-NP
O	427	430	DNA	DNA	NN	I-NP
O	431	439	sequence	sequence	NN	I-NP
O	440	442	of	of	IN	B-PP
O	443	448	viral	viral	JJ	B-NP
O	449	458	oncogenes	oncogene	NNS	I-NP
O	459	462	and	and	CC	O
O	463	469	normal	normal	JJ	B-NP
O	470	475	human	human	JJ	I-NP
O	476	482	genome	genome	NN	I-NP
O	483	485	of	of	IN	B-PP
O	486	489	non	non	AFX	B-NP
O	489	490	-	-	HYPH	I-NP
O	490	501	transformed	transform	VBN	I-NP
B-Cell	502	507	cells	cell	NNS	I-NP
O	508	516	revealed	reveal	VBD	B-VP
O	517	521	high	high	JJ	B-NP
O	522	530	sequence	sequence	NN	I-NP
O	531	543	similarities	similarity	NNS	I-NP
O	544	546	in	in	IN	B-PP
O	547	555	specific	specific	JJ	B-NP
O	556	563	genomic	genomic	JJ	I-NP
O	564	569	areas	area	NNS	I-NP
O	569	570	,	,	,	O
O	571	576	which	which	WDT	B-NP
O	577	581	were	be	VBD	B-VP
O	582	587	named	name	VBN	I-VP
B-Cell	588	596	cellular	cellular	JJ	B-NP
O	597	602	proto	proto	AFX	I-NP
O	602	603	-	-	HYPH	I-NP
O	603	611	oncogens	oncogen	NNS	I-NP
O	611	612	.	.	.	O

O	613	617	They	They	PRP	B-NP
O	618	621	are	be	VBP	B-VP
O	622	631	important	important	JJ	B-NP
O	632	642	components	component	NNS	I-NP
O	643	645	of	of	IN	B-PP
O	646	649	the	the	DT	B-NP
O	650	656	growth	growth	NN	I-NP
O	657	667	regulatory	regulatory	JJ	I-NP
O	668	676	pathways	pathway	NNS	I-NP
O	677	679	in	in	IN	B-PP
O	680	686	normal	normal	JJ	B-NP
B-Cell	687	692	cells	cell	NNS	I-NP
O	692	693	.	.	.	O

O	694	697	The	The	DT	B-NP
O	698	710	accumulation	accumulation	NN	I-NP
O	711	713	of	of	IN	B-PP
O	714	721	genetic	genetic	JJ	B-NP
O	722	733	alterations	alteration	NNS	I-NP
O	734	736	of	of	IN	B-PP
O	737	741	some	some	DT	B-NP
O	742	747	proto	proto	AFX	I-NP
O	747	748	-	-	HYPH	I-NP
O	748	756	oncogens	oncogen	NNS	I-NP
O	756	757	,	,	,	O
O	758	762	like	like	IN	B-PP
O	763	766	the	the	DT	B-NP
O	767	771	erbB	erbB	NN	I-NP
O	771	772	-	-	HYPH	B-NP
O	772	778	family	family	NN	I-NP
O	778	779	,	,	,	O
O	780	783	may	may	MD	B-VP
O	784	786	be	be	VB	I-VP
O	787	791	part	part	NN	B-NP
O	792	794	of	of	IN	B-PP
O	795	798	the	the	DT	B-NP
O	799	808	mechanism	mechanism	NN	I-NP
O	808	809	,	,	,	O
O	810	812	by	by	IN	B-PP
O	813	818	which	which	WDT	B-NP
B-Cell	819	828	malignant	malignant	JJ	B-NP
I-Cell	829	834	cells	cell	NNS	I-NP
O	835	838	can	can	MD	B-VP
O	839	846	acquire	acquire	VB	I-VP
O	847	848	a	a	DT	B-NP
O	849	858	selective	selective	JJ	I-NP
O	859	865	growth	growth	NN	I-NP
O	866	875	advantage	advantage	NN	I-NP
O	875	876	.	.	.	O

O	877	880	The	The	DT	B-NP
O	881	890	epidermal	epidermal	JJ	I-NP
O	891	897	growth	growth	NN	I-NP
O	898	904	factor	factor	NN	I-NP
O	905	913	receptor	receptor	NN	I-NP
O	914	915	(	(	(	O
O	915	918	EGF	EGF	NN	B-NP
O	918	919	-	-	HYPH	B-NP
O	919	920	R	R	NN	I-NP
O	920	921	,	,	,	O
O	922	923	c	c	NN	B-NP
O	923	924	-	-	HYPH	I-NP
O	924	929	erbB1	erbB1	NN	I-NP
O	929	930	)	)	)	O
O	930	931	,	,	,	O
O	932	935	Her	Her	PRP$	B-NP
O	935	936	-	-	SYM	I-NP
O	936	937	2	2	CD	I-NP
O	937	938	/	/	SYM	I-NP
O	938	941	neu	neu	NN	I-NP
O	942	943	(	(	(	O
O	943	944	c	c	NN	O
O	944	945	-	-	HYPH	O
O	945	950	erbB2	erbB2	NN	B-NP
O	950	951	)	)	)	O
O	951	952	,	,	,	O
O	953	956	and	and	CC	O
O	957	958	c	c	NN	B-NP
O	958	959	-	-	HYPH	I-NP
O	959	964	erbB3	erbB3	NN	I-NP
O	965	968	are	be	VBP	B-VP
O	969	976	members	member	NNS	B-NP
O	977	979	of	of	IN	B-PP
O	980	983	the	the	DT	B-NP
O	984	988	erbB	erbB	NN	I-NP
O	988	989	-	-	HYPH	B-NP
O	989	995	family	family	NN	I-NP
O	995	996	.	.	.	O

O	997	1000	The	The	DT	B-NP
O	1001	1010	detection	detection	NN	I-NP
O	1011	1013	of	of	IN	B-PP
O	1014	1023	increased	increase	VBN	B-NP
O	1024	1033	abundance	abundance	NN	I-NP
O	1034	1036	of	of	IN	B-PP
O	1037	1040	EGF	EGF	NN	B-NP
O	1040	1041	-	-	HYPH	B-NP
O	1041	1042	R	R	NN	I-NP
O	1043	1045	or	or	CC	O
O	1046	1049	Her	Her	PRP$	B-NP
O	1049	1050	-	-	SYM	I-NP
O	1050	1051	2	2	CD	I-NP
O	1051	1052	/	/	SYM	I-NP
O	1052	1055	neu	neu	NN	I-NP
O	1056	1064	proteins	protein	NNS	I-NP
O	1065	1067	in	in	IN	B-PP
O	1068	1073	human	human	JJ	B-NP
B-Cancer	1074	1081	tumours	tumour	NNS	I-NP
O	1082	1085	can	can	MD	B-VP
O	1086	1093	provide	provide	VB	I-VP
O	1094	1104	additional	additional	JJ	B-NP
O	1105	1116	information	information	NN	I-NP
O	1117	1119	on	on	IN	B-PP
O	1120	1123	the	the	DT	B-NP
O	1124	1131	disease	disease	NN	I-NP
O	1131	1132	-	-	HYPH	B-NP
O	1132	1136	free	free	JJ	I-NP
O	1137	1145	survival	survival	NN	I-NP
O	1146	1149	and	and	CC	O
O	1150	1157	overall	overall	JJ	B-NP
O	1158	1166	survival	survival	NN	I-NP
O	1167	1170	for	for	IN	B-PP
O	1171	1179	patients	patient	NNS	B-NP
O	1180	1184	with	with	IN	B-PP
B-Cancer	1185	1191	breast	breast	NN	B-NP
O	1191	1192	,	,	,	O
B-Cancer	1193	1200	ovarian	ovarian	JJ	B-NP
O	1200	1201	,	,	,	I-NP
B-Cancer	1202	1213	endometrial	endometrial	JJ	I-NP
O	1214	1216	or	or	CC	I-NP
B-Cancer	1217	1225	cervical	cervical	JJ	I-NP
I-Cancer	1226	1232	cancer	cancer	NN	I-NP
O	1232	1233	.	.	.	O

O	1234	1243	Molecular	Molecular	JJ	B-NP
O	1244	1247	and	and	CC	I-NP
B-Cell	1248	1252	cell	cell	NN	I-NP
O	1252	1253	-	-	HYPH	B-NP
O	1253	1266	physiological	physiological	JJ	I-NP
O	1267	1275	analyses	analysis	NNS	I-NP
O	1276	1280	have	have	VBP	B-VP
O	1281	1289	improved	improve	VBN	I-VP
O	1290	1293	the	the	DT	B-NP
O	1294	1307	understanding	understanding	NN	I-NP
O	1308	1310	of	of	IN	B-PP
B-Cancer	1311	1317	tumour	tumour	NN	B-NP
O	1318	1325	biology	biology	NN	I-NP
O	1326	1329	and	and	CC	O
O	1330	1337	provide	provide	VBP	B-VP
O	1338	1341	the	the	DT	B-NP
O	1342	1353	opportunity	opportunity	NN	I-NP
O	1354	1357	for	for	IN	B-PP
O	1358	1361	new	new	JJ	B-NP
O	1362	1373	therapeutic	therapeutic	JJ	I-NP
O	1374	1384	approaches	approach	NNS	I-NP
O	1384	1385	.	.	.	O

O	1386	1396	Monoclonal	Monoclonal	JJ	B-NP
O	1397	1405	antibody	antibody	NN	I-NP
O	1406	1414	targeted	target	VBD	B-VP
O	1415	1422	therapy	therapy	NN	B-NP
O	1423	1431	directed	direct	VBN	B-VP
O	1432	1439	against	against	IN	B-PP
O	1440	1443	EGF	EGF	NN	B-NP
O	1443	1444	-	-	HYPH	B-NP
O	1444	1445	R	R	NN	I-NP
O	1446	1448	or	or	CC	O
O	1449	1452	Her	Her	PRP$	B-NP
O	1452	1453	-	-	SYM	I-NP
O	1453	1454	2	2	CD	I-NP
O	1454	1455	/	/	SYM	I-NP
O	1455	1458	neu	neu	NN	I-NP
O	1458	1459	,	,	,	O
O	1460	1463	the	the	DT	B-NP
O	1464	1467	use	use	NN	I-NP
O	1468	1470	of	of	IN	B-PP
O	1471	1475	anti	anti	AFX	B-NP
O	1475	1476	-	-	HYPH	I-NP
O	1476	1481	sense	sense	NN	I-NP
O	1482	1498	oligonucleotides	oligonucleotide	NNS	I-NP
O	1499	1502	and	and	CC	I-NP
O	1503	1524	oligodeoxynucleotides	oligodeoxynucleotide	NNS	I-NP
O	1524	1525	,	,	,	O
O	1526	1529	and	and	CC	O
O	1530	1533	the	the	DT	B-NP
O	1534	1545	application	application	NN	I-NP
O	1546	1548	of	of	IN	B-PP
O	1549	1557	tyrosine	tyrosine	NN	B-NP
O	1558	1564	kinase	kinase	NN	I-NP
O	1565	1568	and	and	CC	O
O	1569	1576	protein	protein	NN	B-NP
O	1577	1578	C	C	NN	I-NP
O	1578	1579	-	-	HYPH	B-NP
O	1579	1585	kinase	kinase	NN	I-NP
O	1586	1596	inhibitors	inhibitor	NNS	I-NP
O	1597	1600	are	be	VBP	B-VP
O	1601	1610	currently	currently	RB	I-VP
O	1611	1616	being	be	VBG	I-VP
O	1617	1629	investigated	investigate	VBN	I-VP
O	1629	1630	.	.	.	O

